Boston Scientific Corporation (BSX)

Boston Scientific's stock has shown strong performance, outperforming the Medical Product industry and the S&P 500. As of June 25, 2025, the share price was $104.29, a 35.27% increase from June 26, 2024. Key events impacting the stock price include the Q4 2024 and Q1 2025 earnings announcements, the acquisition of Axonics, FDA approval of FARAPULSE, CFO retirement and succession, upcoming investor conference schedule, Chairman's intention to sell stock, and the acquisition of Silk Road Medical, Inc.

Demand for Boston Scientific's products does not exhibit significant seasonality. The demand is consistently strong and growing, driven by aging demographics, the preference for minimally invasive procedures, technological innovation, and international expansion.

Boston Scientific Corporation is a global healthcare company specializing in less-invasive medical devices. Its mission is to transform lives through innovative medical solutions. The company's portfolio addresses cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. Its operations are divided into MedSurg and Cardiovascular segments. The Cardiovascular segment includes products for interventional cardiology, cardiac rhythm management, electrophysiology, and peripheral interventions. The MedSurg segment encompasses endoscopy, urology and pelvic health, and neuromodulation. Boston Scientific generates revenue by selling its devices to hospitals, clinics, and outpatient facilities globally.

Boston Scientific has a significant global presence with approximately 53,000 employees across six continents and a market presence in approximately 125 to 140 countries. Its global corporate headquarters are in Marlborough, Massachusetts, with regional headquarters in Singapore and Paris. Major technology centers are located in Minnesota, California, Ireland, and Costa Rica, and the company operates 13 manufacturing facilities globally. In 2024, it saw double-digit operational net sales growth in the United States, Europe, Middle East, and Africa, Asia Pacific, and Latin America and Canada. Emerging markets, in particular, showed robust growth in 2024 and continued to register sturdy growth in the first quarter of 2025.

Boston Scientific has a strong reputation as a global leader in medical technology, known for innovative products and ethical practices. Its brand has been positively impacted by innovative product development, strong financial performance, strategic acquisitions, and credit rating upgrades. No significant negative events impacting the brand were found.

Boston Scientific has a mixed ownership structure, with institutional investors holding the largest share, ranging from 71.07% to 88.93%. Insiders own about 0.16% to 5.72%, and public companies and individual investors hold the remaining shares (22.17% to 28.76% retail investors). Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Fmr Llc. Promerica LP is the largest individual shareholder, owning 54.64 million shares, representing 3.69% of the company.